Literature DB >> 23446910

Prognostic value of post-procedural aPTT in patients with ST-elevation myocardial infarction treated with primary PCI.

W J Kikkert1, S H van Nes, K V V Lieve, G D Dangas, J van Straalen, M Vis, J Baan, K T Koch, R J de Winter, J J Piek, J G P Tijssen, J P Henriques.   

Abstract

Unfractionated heparin is the most commonly used anticoagulant in ST-elevation myocardial infarction (STEMI) and its effect can be monitored with activated partial thromboplastin time (aPTT). However, the optimal aPTT range during heparin therapy after primary percutaneous coronary intervention (PCI) is yet to be defined. A mean aPTT was calculated of all aPTT measurements in the first 24 hours after pPCI in a total of 1,876 STEMI patients. Mean aPTT measurements were stratified into four categories; < 1.5 times the upper limit of normal (ULN), 1.5 - 2.0 times ULN (the therapeutic group), 2.01 - 3.99 times ULN, and ≥ 4 times ULN. Compared to patients with a therapeutic aPTT, patients with aPTTs < 1.5 times ULN had no increase in recurrent ischaemic events and had similar rates of bleeding complications. Patients with a mean aPTT ≥ 4 times ULN had higher rates recurrent ischaemic and haemorrhagic complications. After multivariable analyses, aPTT ratios ≥ 4 times ULN were no longer associated with recurrent ischaemic events, but remained a strong predictor of severe and moderate bleeding (hazard ratio [HR] 4.64, p = 0.016 and HR 2.27, p = 0.052). In conclusion, in 1,876 STEMI patients treated with pPCI, low aPTTs in the first 24 hours after PCI were not associated with an increase in ischaemic events, whereas high aPTT values were associated with more frequent bleeding complications. These results indicate no clear benefit as well as a safety concern with heparin treatment after primary PCI.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23446910     DOI: 10.1160/TH12-10-0726

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  4 in total

1.  Influence of Body Mass Index on the Activated Clotting Time Under Weight-Based Heparin Dose.

Authors:  Xia Hong; Pei-Ren Shan; Wei-Jian Huang; Qian-Li Zhu; Fang-Yi Xiao; Sheng Li; Hao Zhou
Journal:  J Clin Lab Anal       Date:  2014-11-25       Impact factor: 2.352

2.  Long-term ischaemic and bleeding outcomes after primary percutaneous coronary intervention for ST-elevation myocardial infarction in the elderly.

Authors:  Bimmer E P M Claessen; Wouter J Kikkert; Loes P Hoebers; Hassina Bahadurzada; Marije M Vis; Jan Baan; Karel T Koch; Robbert J de Winter; Jan G P Tijssen; Jan J Piek; José P S Henriques
Journal:  Neth Heart J       Date:  2015-09       Impact factor: 2.380

3.  Admission lipoprotein-associated phospholipase A2 activity is not associated with long-term clinical outcomes after ST-segment elevation myocardial infarction.

Authors:  Pier Woudstra; Peter Damman; Wichert J Kuijt; Wouter J Kikkert; Maik J Grundeken; Peter M van Brussel; An K Stroobants; Jan P van Straalen; Johan C Fischer; Karel T Koch; José P S Henriques; Jan J Piek; Jan G P Tijssen; Robbert J de Winter
Journal:  PLoS One       Date:  2014-05-01       Impact factor: 3.240

4.  Influence of chronic kidney disease on anticoagulation levels and bleeding after primary percutaneous coronary intervention in patients treated with unfractionated heparin.

Authors:  Wouter J Kikkert; Peter M van Brussel; Peter Damman; Bimmer E Claessen; Jan P van Straalen; Marije M Vis; Jan Baan; Karel T Koch; Ron J Peters; Robbert J de Winter; Jan J Piek; Jan G P Tijssen; Jose P S Henriques
Journal:  J Thromb Thrombolysis       Date:  2016-04       Impact factor: 2.300

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.